Genta has announced that the eighth non-Hodgkin's lymphoma patient to be treated in its ongoing G3139 Phase I/IIa trial at the Royal Marsden Hospital in London, UK, has achieved a complete response. Additionally, four out of eight evaluable patients have demonstrated clinical and/or biological activity, with no dose-limiting toxicity.
The dose-escalating, open-label study is enrolling patients with advanced disease who have failed prior conventional treatments. Patients are being treated with G3139 for two weeks via subcutaneous infusion. Nine patients have been treated to date, with the most recent group of three patients receiving a dosage 16 times that of the original dose.
The trial is expected to continue until the maximum tolerated dose is determined. G3139 targets the BCL2 gene, which is thought to play an important role in the development of lymphoma and its resistance to chemotherapy and radiation. High levels of BCL2 are associated with a poor clinical prognosis for some lymphoma patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze